DPP4 and metabolic dysfunction-associated steatotic liver disease: Studies have also indicated a reduced efficacy of certain treatments in NAFLD condition, such as the novel oral hypoglycemic sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.